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number and length of health-care visits. For our analysis,
the total time spent with a primary health-care profes-
sional was calculated. Centers for Epidemiologic Studies –
Depression (CES-D, representing symptom-based severity
of depression) and Quality of Life Depression Scale
(QLDS, depression-specific quality of life) data were
gathered from a sample of patients self-reporting depres-
sive symptoms, but not necessarily having a diagnosis of
depression.
RESULTS: Using the cross-sectional baseline measure-
ment point, a total of 2359 patients were evaluated
across the sites. Dividing the population by CES-D scores
(20, 20), all sites except St. Petersburg had a pattern
where those with lower CES-D scores (less depressive
symptomatology) spent less time with their doctors than
those with more moderate to severe depression (ranging
from 1 minute in Barcelona to over 10 minutes in Seat-
tle). Comparing groups split by mean quality of life
scores, a similar pattern was noted with those having
lower quality of life spending less time with their health
care provider (1 minute in Melbourne to 10 minutes in
Seattle).
CONCLUSION: With the exception of the site in St. Pe-
tersburg, primary care patients who self-report depressive
symptoms and lower quality of life tend to spend more
actual contact time with their health-care providers.
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OBJECTIVE: Major depressive disorder (MDD) is a de-
bilitating condition with significant economic conse-
quences. Estimates indicate that up to 30% of individuals
with MDD are treatment resistant (TRD). The study ob-
jectives were (a) evaluation of studying TRD using claims
data; (b) estimation of cost differences between TRD and
non-TRD patients.
METHODS: Data source was administrative claims data
from a Fortune 100 manufacturer. Claims included medi-
cal, pharmaceutical and disability claims for 1996–1998
(n  100,000). The sample was restricted to claims for
MDD (NMDD  4,186). Using a treatment algorithm,
patients were classified into TRD-likely and TRD-unlikely
groups (NTRD  487). Resource utilization was com-
pared between TRD-likely, TRD-unlikely patients, and a
sample of the overall population.
RESULTS: The algorithm classified twelve percent of the
MDD sample as TRD. Average annual costs were $10,954
for TRD-likely patients, $5,025 for TRD-unlikely pa-
tients, and $3006 for average beneficiaries. The average
number of health claims among TRD-likely patients were
one and a half times greater than that of TRD-unlikely
patients.
CONCLUSION: Resource utilization by TRD-likely pa-
tients is substantial, not only for direct treatment of de-
pression but also for treatment of co-morbid medical
conditions. Additionally, TRD imposes substantial indi-
rect costs on employers, primarily resulting from high
rates of depression-associated disability.
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OBJECTIVE: To compare Adverse Drug Events (ADE)
associated with Selective Serotonin Reuptake Inhibitors
(SSRI) in two Managed Care Organizations (MCO).
METHODS: Medical records for two MCOs in central
Texas were reviewed. Scott and White Health Plan
(SWHP) is a general health plan and Alamo Mental
Health Group (AMHG) is a behavioral/mental health or-
ganization. Inclusion criteria for both settings were pa-
tients over 18 years old that had a diagnosis of depres-
sion and had a new prescription for an SSRI.
RESULTS: A total of 337 patients in SWHP and 361 pa-
tients in AMHG met the inclusion criteria. About 40%
(N  135) of SWHP patients and 40% (N  144) of
AMHG patients had at least one adverse drug event
(ADE) associated with an SSRI noted in their medical
record. The most common ADEs reported were sleep cy-
cle disturbances, e.g. insomnia, daytime sedation 13(%);
GI disturbances, e.g. diarrhea, nausea/vomiting 11(%);
sexual dysfunction 7(%); and anxiety/nervousness 5(%).
Of those with reported ADEs (N  135  144  279), at
least one therapy change due to ADEs was made for 71%
(N  96) of the SWHP patients and 69% (N  100) of
the AMHG patients: 25% were switched to another anti-
depressant; 20% had a medication added; 19% had a
change in the dose/regimen of their index medication;
12% discontinued their index medication. The most
common medication added to treat side effects at SWHP
was trazodone, while the most common addition at
AMHG was bupropion.
CONCLUSIONS: Although the health-care settings dif-
fered in type (general versus behavioral/mental health), re-
sults were strikingly similar. About 40% of the patients re-
ported ADEs and of these, about 70% had at least one
change made to their therapy, many discontinuing the
original medication. Strategies for treating ADEs appeared
to vary by setting, which may have cost implications. Fu-
ture research might examine the impact of ADE strategies
and patient education on continuity of treatment.
